Phase III Comparison of Twice-Daily Split-Course Irradiation Versus Once-Daily Irradiation for Patients With Limited Stage Small-Cell Lung Carcinoma

Abstract

When TI is delayed until the fourth cycle of chemotherapy, TDTI does not result in improvement in local control or survival compared with ODTI.

Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists

“…However, Colaco et al 31 also evaluated the omission of eni based on ct imaging in a subset of 31 patients enrolled on the convert trial. That report demonstrated no infs and lower rates of acute grade 3 esophagitis and pneumonitis compared with historical data [25][26][27] . Given the conflicting findings, further investigation with large prospective rcts to address the issue of omitting eni is important.…”

“…The clinical rationale for eni is to attempt to lower the rate of isolated nodal failures (infs) by prophylactically irradiating radiographically uninvolved locoregional micrometastatic disease 18,[25][26][27] . The use of eni raises a clinical dilemma, however, because larger treatment volumes can result in greater rt-related toxicity, and omission of eni can potentially increase the risk of infs outside the treated volume.…”

Small Cell Lung Cancer: Current Therapy and Promising New Regimens

“…Recently, two different cooperative groups randomized patients to once-a-day versus twice-a-day TRT with standard chemotherapy for all patients [12,13]. Turrisi et al [12] reported the long-term follow-up of patients enrolled in the Eastern Cooperative Oncology Group/Radiation Therapy Oncology Group (ECOG/RTOG) trial ( Table 1) and concluded that twice-a-day radiotherapy resulted in a statistically better 5-year survival.…”

“…All patients received four cycles of EP chemotherapy (two concurrent with radiotherapy), and TRT began on day 1 of treatment. Bonner and associates [13] reported the North Central Cancer Treatment Group (NCCTG) experience and concluded that there was no difference in survival with twicedaily TRT versus once-daily radiotherapy. All patients received identical chemotherapy with six cycles of etoposide and cisplatin (Table 1).…”

Radiation Therapy in Management of Small-Cell Lung Cancer

“…Laboratory studies have suggested that typical SCLC cell lines have radiation survival curves with little shoulders indicating that accelerated fractionation schemes would, therefore, be advantageous (van Meerbeeck et al, 2011). In 1999, two different cooperative groups randomized patients to once-a-day versus twice-aday TRT with concurrent chemotherapy, as depicted in Table 1 (Bonner, 1999;Turrisi, 1999). In the study by Bonner et al, authors reported the North Central Cancer Treatment Group (NCCTG) experience, and concluded that there was no difference in survival with twicedaily TRT versus once daily counterpart (Bonner et al, 1999).…”